Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish proof of efficacy for namilumab in moderate to
severe plaque psoriasis, measured as Psoriasis Area and Severity Index (PASI)75 response rate
at Week 12.